Evidence-Based Complementary and Alternative Medicine

Evidence-Based Complementary and Alternative Medicine / 2020 / Article
Special Issue

Natural Products and Tissue Repair: Identification, Relevance and Applicability

View this Special Issue

Research Article | Open Access

Volume 2020 |Article ID 2407239 | https://doi.org/10.1155/2020/2407239

Yan-jun Wang, Yang Li, Xue-lin Wang, Xin-ze Li, Yan-wen Chen, Ling-ling Yang, Hai-xia Ming, "Effect of Total Flavonoids of Oxytropis falcata Bunge on the Expression of p-JAK1-and p-STAT1-Related Proteins in Idiopathic Pulmonary Fibrosis", Evidence-Based Complementary and Alternative Medicine, vol. 2020, Article ID 2407239, 10 pages, 2020. https://doi.org/10.1155/2020/2407239

Effect of Total Flavonoids of Oxytropis falcata Bunge on the Expression of p-JAK1-and p-STAT1-Related Proteins in Idiopathic Pulmonary Fibrosis

Guest Editor: Reggiani Vilela Gonçalves
Received22 May 2020
Accepted07 Jul 2020
Published28 Aug 2020

Abstract

Objective. The study aimed to explore the effect of total flavonoids of Oxytropis falcata Bunge (FOFB) on the expression of p-JAK1/p-STAT1 and SOCS3 proteins in idiopathic pulmonary fibrosis (IPF). Methods. Rats model with IPF was established by one-off intratracheal injection of bleomycin (BLM, 5 mg/kg). After 14 days, the same volume of low dose (100 mg/kg), medium dose (200 mg/kg), and high dose (400 mg/kg) of FOFB and prednisolone acetate (20 mg/kg) as positive control drugs, as well as normal saline, were orally administered to rats once a day for 28 consecutive days. Subsequently, the degree of fibrosis and alveolitis in rat lung tissue was observed, respectively, by HE and Masson staining. Further more, observing the ultrastructure of lung tissue by transmission electron microscopy (TEM), the detection of JAK/STAT pathway related indicators including p-JAK1, p-STAT1, and SOCS3 with immunohistochemistry and SOCS3 with real-time PCR (RT-PCR) was performed. Results. Compared with the BLM group, the degree of alveolitis and fibrosis improved significantly, and the expression of p-JAK1 and p-STAT1 decreased; conversely, the expression of SOCS3 increased in the treatment group. Conclusion. IPF causes high expression of p-JAK1 and p-STAT1 and low expression of SOCS3. FOFB can play a role in the treatment of IPF via upregulating SOCS3 and downregulating p-JAK1 and p-STAT1.

1. Introduction

Idiopathic pulmonary fibrosis (IPF), characterized by progressive dyspnea, is a chronic progressive interstitial lung disease [1]. After diagnosis, without a lung transplant, the median survival rate is 3–5 years, and the patient eventually dies from respiratory failure [2]. Nowadays, the specific etiology and pathogen are still unknown [3]. Most studies suggest that the occurrence of IPF is characterized by repeated subclinical damage to the alveolar epithelium [46]. After the lung tissue is damaged, the alveolar epithelium cell is activated. On the one hand, chemokines are released to recruit fibroblasts (FB) and a large number of FB subsequently can produce extracellular matrix (ECM). Besides, FB can also be transformed into myofibroblasts (MFB) under the induction of fibrogenic factors (such as transforming growth factor-β) generating ECM [7]. The excessive deposition of ECM accelerates the occurrence of pulmonary fibrosis. Several key signaling pathways play important role in the regulation process, including JAK/STAT, NF/κB, and MAPK signaling pathways [8]. Among them, the JAK/STAT signal pathway is most closely related to the occurrence of IPF [9].

JAK protein kinas has a molecular weight of 120–130 kDa. So far, four members, JAK1, JAK2, JAK3, and TYK2, have been identified, which play important and diverse functions in hematopoietic, inflammatory, and immune responses. Among them, JAK1 is the most expressed JAK kinase, which is related to the signal transduction process of many cytokines and involved in inflammation and immune deficiency. STATs have a molecular weight between 79 and 113 kDa, and members of seven STAT protein families including STAT1, STAT2, STAT3, STAT4, STAT5A, STAT5B, and STAT6 have been found. STAT1 is the earliest discovered and cloned member of the STAT family [10]. Animal experiments have shown that STAT1 is abnormally expressed in bleomycin- (BLM-) induced IPF mice [11]. JAK1 is inactive before being exposed to cytokines, but the binding of cytokines to their receptors induces their own activation through transphosphorylation (i.e., formation of p-JAK1). Activated p-JAK1 phosphorylates its downstream signaling protein STAT1 (i.e., forming p-STAT1), causing them to dissociate from the receptor and transport to the nucleus. Then, p-STAT1 acts as a transcription factor in the nucleus to induce transcription of the target gene [12]. The SOCS protein family (especially SOCS3) is the most widely known negative regulator of the JAK/STAT pathway [13]. In addition, SOCS3 also has the ability to directly inhibit JAK kinase activity [14].

Total flavonoids of Oxytropis falcata Bunge (FOFB), extracts of Oxytropis falcata Bunge, are the major active components. Studies have confirmed that it has multiple pharmacologic actions, including being antitumor, being antioxidant, improvement of insulin resistance, protection against UV damage, enhancement of immune cofunction, being anti-inflammatory, and analgesia [15, 16]. Among them, the anti-inflammatory effect is the most significant. Other studies have shown that FOFB can reduce the expression of profibrosis factors such as typeIand type III collagen, inhibit TGF-β1-induced human renal tubular epithelial cell proliferation, and slow down the progress of fibrosis [17, 18]. Inflammation plays an irreplaceable role in the process of IPF, and FOFB has a significant anti-inflammatory effect. However, whether FOFB can exert IPF-preventing effects by affecting the expression of inflammatory factors, such as p-JAK1/p-STAT1 and SOCS3, is still unclear.

In the current study, to clarify the specific effects of FOFB on the Inflammation related protein including p-JAK1, p-STAT1, and SOCS3, rats models with IPF were established with BLM. This study aims to find specific targets that block the JAK-STAT signaling pathway in inflammation and provide an experimental basis for the treatment of IPF.

2. Material and Methods

2.1. Animals

Sixty adult specific pathogen-free animal (SPF) Sprague Dawley (SD) rats in half genders (200 ± 20 g) were provided by the Experimental Animal Center of Gansu University of Chinese Medicine. The environmental temperature was controlled at 25 ± 2°C, humidity was maintained at 45%–55%, and circadian rhythm was 12:12 h dark/light. All rats were fed with sterilized diet and water. Animal welfare was in compliance with the principles and procedures of Health Guide for the Care and Use of Laboratory Animals. The study protocols were approved by the Animal Care and Use Committee of Gansu University of Chinese Medicine.

2.2. Chemicals and Reagents

Oxytropis falcata Bunge was purchased from Tianzhu County Tibetan Medicine Development Institute. Total flavonoids of Oxytropis falcata Bunge (FOFB) were extracted and identified by Lanzhou University. The extraction method was ethanol immersion. The specific process included putting 5000 grams of medicinal materials in a 5000 mL round-bottom flask, immersing in 10 times the amount of absolute ethanol, soaking for 3 days, repeating 3 times, taking the filtrate, and spin-drying to obtain the product. Bleomycin was obtained from Nippon Kayaku (Tokyo, Japan). Prednisone was purchased from Zhejiang Xianju Pharmaceutical Co., Ltd., Zhejiang, China. Rabbit antibodies of p-JAK1/p-STAT1 and SOCS3 were purchased from Abcam plc, Cambridge, UK.

2.3. Grouping and Medications

Rats were randomly divided into six groups including blank (control) group, model (BLM) group, low-dose FOFB (100 mg/kg) group, middle-dose FOFB (200 mg/kg) group, high-dose FOFB (400 mg/kg) group, and prednisone acetate group (20 mg/kg) with 10 rats in each group. After intraperitoneal anesthesia with 3% pentobarbital sodium (30 mg/kg), the rats were fixed in supine position. With the help of laryngoscope, BLM (5 mg/kg) was injected into the trachea. The control group was given the same volume of physiological saline. After the injection, the animal was straightened and immediately rotated left and right to distribute the lung fluid evenly. After 14 days of modeling, rats in each group were given 2 mL of corresponding dose of drugs by gavage once daily. All rats were sacrificed on day 28.

2.4. Histopathology

After sacrifice, part of the left lung tissue was fixed in 4% paraformaldehyde, subsequently embedded in paraffin, serially sectioned, and stained with hematoxylin and eosin (H&E) or Masson’s trichrome staining kit (Sigma-Aldrich) following manufacture's protocol. Histopathologic score was graded by specialized histopathologists blindly referring to Szapiel’s semiquantitative grading system to divide into 4 grades and described the fibrosis score. The slices stained by Masson’s trichrome were picked-up pictures by camera of microscope system and processed by Image-Pro plus version 6.0 for Windows.

2.5. Transmission Electron Microscope

Parts of lung tissue specimen was fixed by 2.5% glutaraldehyde, followed by 1% osmic acid postfixation, routinely dehydrated, and embedded in epoxy resin. It was then sliced into ultrathin sections and observed by a transmission electron microscope and images by AMT camera system were saved.

2.6. Immunohistochemistry

Lung tissue was sliced and dewaxed to water (xylene I 15 min, xylene II 15 min, xylene III 15 min, absolute ethanol I 5 min, absolute ethanol II 5 min, 85% alcohol 5 min, 75% alcohol 5 min, and distilled water). After repairing with citric acid antigen repair buffer, add 3% hydrogen peroxide to incubate. After blocking at room temperature for 30 minutes and adding rabbit polyclonal anti-p-JAK1 (1 : 200 vol/vol, Abcam), anti-p-STAT1 (1 : 100 vol/vol, Abcam), and anti-SOCS3 (1 : 100 vol/vol, Abcam), put it in a wet box at 4°C refrigerator overnight. After washing with PBS, adding secondary antibody (goat anti-rabbit) (1 : 200), DAB color development, and observing under the microscope, the reaction was terminated when it showed brown. Then, hematoxylin counterstained and returned to blue, and the neutral resin sealed.

2.7. Reverse Transcription Polymerase Chain Reaction (RT-PCR)

Total RNA extraction and cDNA synthesis were performed according to kit instructions. Semiquantitative PCR primers were designed according to SOCS3 cDNA sequence in NCBI. The SOCS3 primer was 5′-TCTTTACCACCgACggAACC-3′ and 5′-gTACCAgCgggATCTTCTCg-3'. The internal control GAPDH primer was 5′-AgTgCCAgCCTCgTCTCATA-3′ and 5′-TTgTCACAAgAgAAggCAgC-3'. For the PCR reaction, 2 μl of cDNA, 2 μl of primer, and 10 μl of 2 × PCR Master Mix were added to 20 μl of dd H2O. The reaction conditions were as follows: 95°C denaturation for 5 min, 95°C denaturation for 10 s, 60°C annealing for 20 s, 72°C extension for 20 s, and 42 cycles.

2.8. Statistical Analysis

All data conforming to normal distribution were presented as mean ± standard deviation (SD), and those not conforming to normal distribution were represented by median and interquartile spacing. Data were analyzed by one-way analysis of variance (ANOVA) of the SPSS 24.0 software. Statistical difference was considered significant when value is less than 0.05.

3. Results

3.1. FOFB Ameliorated the Progress of Inflammation and Fibrosis in BLM-Induced IPF in Rats

We assessed the extent of inflammation in the lung tissue with HE staining. As shown in Figure 1. The picture of control group showed the bronchial and alveolar structures were intact, the alveolar septum was not thickened, and occasionally inflammatory cell infiltration was observed under the microscope. Sample of BLM group shows most of the alveolar structures collapsed and fused, and the interstitial cells increased, showing obvious fibrosis; the alveolar septa were significantly widened and thickened, and the infiltration of inflammatory cells increased significantly. Compared with the BLM group, low-dose FOFB group showed no significant difference; middle-/high-dose FOFB group and prednisone group could improve the destruction of alveolar structure and reduce the area of alveolar space and inflammatory cell infiltration, especially in the FOFB high-dose group and prednisone acetate group.

Szapiel score is shown in Table 1. The treatment group with middle-/high-dose FOFB and prednisone groups were lower than BLM group ().


GroupsStaining scoreComparison with blank groupComparison with BLM groupComparison with prednisone acetate groupComparison among groups
M (Q1, Q3)p

Blank group1.00 (1.00, 1.00)<0.00010.98

BLM group3.00 (3.00, 3.00)<0.00010.001

Low-dose group of FOF3.00 (2.00, 3.00)0.0050.7880.004

Middle-dose group of FOF2.00 (2.00, 2.25)0.0080.0360.021

High-dose group of FOF1.00 (1.00, 2.00)0.7880.0051.000

Prednisone acetate group1.00 (1.00, 1.25)0.9800.001

We evaluate the degree of fibrosis of the lung tissue by Masson’s trichrome, as shown in Figure 2. In the blank group, there was no obvious change in the lung tissue of the rats. The collagen layer of the bronchial wall is thin, and a small number of light blue collagen fibers were distributed in the alveolar wall. In the BLM group, a large number of blue, cord-like, and lamellar collagen fibers stained around the bronchus and small blood vessels and in the lung interstitium were diffusely distributed. And there were a large number of alveolar fusions. The area of collagen deposition was decreased in the middle-/high-dose of FOFB and prednisone acetate groups, especially in the latter two groups.

According to the scoring standard of Masson staining, the results are shown in Table 2. There was a significant difference between the highest score of the BLM group and the lowest score of high-dose FOFB and prednisone acetate group ().


GroupsStaining scoreComparison with blank groupComparison with BLM groupComparison with prednisone acetate groupComparison among groups
 ± S

Blank group0.6667 ± 0.8165<0.0010.204

BLM group3.5000 ± 0.5477<0.001<0.001

Low-dose group of FOF3.1667 ± 0.4082<0.0010.393<0.001

Middle-dose group of FOF2.1667 ± 0.40820.0010.0020.014

High-dose group of FOF1.0000 ± 0.89440.393<0.0010.668

Prednisone acetate group1.1667 ± 0.75270.204<0.001

3.2. FOFB Alleviated the Abnormalities of Lamellar Number and Structure in IPF Rats Induced by BLM

Lamellar bodies (LBs) are organelles present in type II alveolar epithelial cells (AECII) and are closely related to the secretion of alveolar surfactant. Specific lamellar bodies are the most direct method to identify whether the secretory function of type AECII is normal. In our experiments, as shown in Figure 3, it was observed that the LBs of the blank group had a normal structure, with a large number, and neatly arranged; while the number of model groups was significantly reduced, the structure was incomplete and the arrangement was disordered. Compared with the BLM group, the number of LBs in the treatment with FOFB and prednisone acetate groups increased, the structure tended to be normal, and the arrangement tended to be neat.

3.3. Effects of FOFB on the Expression of p-JAK1, p-STAT1, and SOCS3 with IPF in Rats

The activated p-JAK1/p-STAT1 protein is closely related to the occurrence of inflammation and studies have shown that these two proteins are also abnormal expression in IPF. SOCS3 is the most recognized negative regulator of this pathway. As shown in Figures 46, in the control group, immunostaining could be observed in tracheal and vascular wall, and interstitial area was exceedingly weakly positive. In contrast, SOCS3 staining in these sites was strongly positive. Compared with the blank group, in the BLM group, immunostaining of p-JAK and p-STAT1 was strongly positive (); SOCS3 staining was weakly positive (). The positive rate expression of each treatment group was between the above two groups, and there was no significant difference between the FOFB high-dose group and the prednisone acetate group and the normal group (Figure 7).

3.4. Effects of FOFB on the Expression of SOCS3 with IPF in Rats

RT-PCR reflected that the mRNA expression of SOCS3 was significantly lower in the lung tissue of the model group than that of the blank group (). The results are shown in Figure 8.

4. Discussion

IPF is an interstitial lung disease with high mortality and poor prognosis [19]. Researchers have found that inflammation was closely related to its occurrence and development [8, 20]. JAK1/STAT1 is a key signaling pathway to regulate inflammation [8]. At the same time, studies have shown that JAK1 and STAT1 are abnormally expressed in the lung tissue of IPF mice [8]. SOCS3 is a negative regulator of JAK1/STAT1 and can block the conduction of this signal pathway [13]. In recent years, Traditional Chinese Medicine plays an important role in the treatment of IPF with its unique advantages and efficacy [21]. Oxytropis falcata Bunge is one of the three anti-inflammatory drugs of Tibetan medicine, among which flavonoids extract has the strongest anti-inflammatory activity [15]. It has been confirmed that FOFB can reduce the expression of some profibrotic factors and slow down the process of renal interstitial fibrosis [18]. Based on the above theory, we investigated the effect of FOFB on the inflammation-induced lung tissue damage, the degree of fibrosis, and the expression of p-JAK1, p-STAT1, and SOCS3.

Intratracheal injection of BLM to establish the IPF model is the most classic method because it is similar to the pathological process of human pulmonary fibrosis [22]. In our study, observing the pathological morphology of lung tissue of BLM-induced IPF rats by HE and Masson staining, we found FOFB group could improve the degree of alveolitis and delay the progress of IPF. The existing research has confirmed that p-JAK1 and p-STAT1 were involved in the formation of IPF. JAK1 is inactive before exposure to cytokines, but the binding of cytokines to their receptors induces their own activation through transphosphorylation. Upon activation, phosphorylated JAK1, named p-JAK1, serve as docking sites for members of the STAT transcription factor family. Receptor-localized STAT1 is then phosphorylated by p-JAK1, named p-STAT1, causing a biochemical cascade [14]. Through the results of immunohistochemistry and RT-PCR, we found that the FOFB group could increase the expression of SOCS3 protein and further reduce the expression of p-JAK1 and p-STAT1 to play a therapeutic role.

5. Conclusion

FOFB has a therapeutic effect on inflammation-mediated idiopathic pulmonary fibrosis, and its mechanism may be to inhibit the expression of p-JAK1 and p-STAT1 inflammatory proteins by upregulating the expression of SOCS3.

Data Availability

All the data related to this article are described as histopathological pictures and statistical analysis in the manuscript.

Ethical Approval

The protocol of the experiment was approved by the Ethical Committee for the Experimental Animals at Gansu University of Traditional Chinese Medicine (Gansu, China) (Approval no. 0001391).

Conflicts of Interest

The authors have declared that no conflicts of interest exist.

Acknowledgments

This study was funded by the National Natural Science Foundation of China (no. 81860830).

Supplementary Materials

Szapiel’s semiquantitative grading system. (Supplementary Materials)

References

  1. W. H. Ma, M. Li, H. F. Ma et al., “Protective effects of GHK-Cu in bleomycin-induced pulmonary fibrosis via anti-oxidative stress and anti-inflammation pathways,” Life Sciences, vol. 241, Article ID 117139, 2020. View at: Publisher Site | Google Scholar
  2. L. Guo, Y. Yang, F. Liu et al., “Clinical research on prognostic evaluation of subjects with IPF by peripheral blood biomarkers, quantitative imaging characteristics and pulmonary function parameters,” Archivos de Bronconeumología, vol. 56, no. 6, pp. 365–372, 2019. View at: Publisher Site | Google Scholar
  3. M. R. Hadjicharalambous, B. T. Roux, E. Csomor et al., “Long intergenic non-coding RNAs regulate human lung fibroblast function: implications for idiopathic pulmonary fibrosis,” Scientific Reports, vol. 9, no. 1, p. 6020, 2019. View at: Publisher Site | Google Scholar
  4. K. M. Milne, C. Chan, J. H. Fisher, K. de Boer, and C. J. Ryerson, “Systematic review of content and quality of idiopathic pulmonary fibrosis review articles,” ERJ Open Research, vol. 4, no. 4, 2018. View at: Publisher Site | Google Scholar
  5. A. Hosseinzadeh, S. A. Javad-Moosavi, R. J. Reiter, K. Hemati, H. Ghaznavi, and S. Mehrzadi, “Idiopathic pulmonary fibrosis (IPF) signaling pathways and protective roles of melatonin,” Life Sciences, vol. 201, pp. 17–29, 2018. View at: Publisher Site | Google Scholar
  6. C. Miao, Y. Xiong, G. Zhang, and J. Chang, “MicroRNAs in idiopathic pulmonary fibrosis, new research progress and their pathophysiological implication,” Experimental Lung Research, vol. 44, no. 3, pp. 178–190, 2018. View at: Publisher Site | Google Scholar
  7. C. Hill, M. Jones, D. Davies, and Y. Wang, “Epithelial-mesenchymal transition contributes to pulmonary fibrosis via aberrant epithelial/fibroblastic cross-talk,” Journal of Lung Health and Diseases, vol. 3, no. 2, pp. 31–35, 2019. View at: Publisher Site | Google Scholar
  8. Y. Ma, T. Tang, L. Sheng et al., “Aloin suppresses lipopolysaccharide-induced inflammation by inhibiting JAK1-STAT1/3 activation and ROS production in RAW2647 cells,” International Journal of Molecular Medicine, vol. 42, no. 4, pp. 1925–1934, 2018. View at: Publisher Site | Google Scholar
  9. G. Yang, L. Lyu, X. Wang et al., “Systemic treatment with resveratrol alleviates adjuvant arthritis-interstitial lung disease in rats via modulation of JAK/STAT/RANKL signaling pathway,” Pulmonary Pharmacology & Therapeutics, vol. 56, pp. 69–74, 2019. View at: Publisher Site | Google Scholar
  10. Q. Gao, X. Liang, A. S. Shaikh, J. Zang, W. Xu, and Y. Zhang, “JAK/STAT signal transduction: promising attractive targets for immune, inflammatory and hematopoietic diseases,” Current Drug Targets, vol. 19, no. 5, pp. 487–500, 2018. View at: Publisher Site | Google Scholar
  11. K. S. Duke, “Mechanisms of carbon nanotube-induced pulmonary fibrosis: a physicochemical characteristic perspective,” Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, vol. 10, no. 3, 2017. View at: Publisher Site | Google Scholar
  12. R. Morris, N. J. Kershaw, and J. J. Babon, “The molecular details of cytokine signaling via the JAK/STAT pathway,” Protein Science, vol. 27, no. 12, pp. 1984–2009, 2018. View at: Publisher Site | Google Scholar
  13. N. P. D. Liau, A. Laktyushin, I. S. Lucet et al., “The molecular basis of JAK/STAT inhibition by SOCS1,” Nature Communications, vol. 9, no. 1, p. 1558, 2018. View at: Publisher Site | Google Scholar
  14. A. R. Almeida-Oliveira, J. Aquino-Junior, A. Abbasi et al., “Effects of aerobic exercise on molecular aspects of asthma: involvement of SOCS-JAK-STAT,” Exercise Immunology Review, vol. 25, pp. 50–62, 2019. View at: Google Scholar
  15. M.-R. Zhang, K. Jiang, J.-L. Yang, and Y.-P. Shi, “Flavonoids as key bioactive components of Oxytropis falcata bunge, a traditional anti-inflammatory and analgesic Tibetan medicine,” Natural Product Research, pp. 1–18, 2019. View at: Publisher Site | Google Scholar
  16. L. Yang, Z. Wang, L. Jiang et al., “Total flavonoids extracted from bunge improve insulin resistance through regulation on the IKK/NF-B inflammatory pathway,” Evidence-based Complementary and Alternative Medicine, vol. 2017, Article ID 2405124, 6 pages, 2017. View at: Publisher Site | Google Scholar
  17. L. Yang, J. Xue, X. Meng et al., “Effects of total flavonoids from Oxytropis falcata Bunge on the SOCS/JAK/STAT inflammatory signaling pathway in the kidneys of diabetic nephropathy model mice,” European Journal of Inflammation, vol. 17, 2019. View at: Publisher Site | Google Scholar
  18. T. Cheng, L. Yang, and L. I Qin, “Effects of drug serum of total flavonoids of oxytropis falcate on VEGF mRNA expression in human renal tubular epithelial cell induced by TGF-β1,” Western Journal of Traditional Chinese Medicine, vol. 30, no. 1, pp. 4–6, 2017. View at: Google Scholar
  19. S. Harari, M. Davì, A. Biffi et al., “Epidemiology of idiopathic pulmonary fibrosis: a population-based study in primary care,” Internal and Emergency Medicine, vol. 15, no. 3, pp. 437–445, 2019. View at: Publisher Site | Google Scholar
  20. P. Heukels, C. C. Moor, J. H. von der Thüsen, M. S. Wijsenbeek, and M. Kool, “Inflammation and immunity in IPF pathogenesis and treatment,” Respiratory Medicine, vol. 147, pp. 79–91, 2019. View at: Publisher Site | Google Scholar
  21. Y. Xiaolin, Z. Yanxia, Y. Xiaohua et al., “The influence of BuqiHuoxueTongluo formula on histopathology and pulmonary function test in bleomycin-induced idiopathic pulmonary fibrosis in rats,” Evidence-Based Complementary and Alternative Medicine, vol. 2018, Article ID 8903021, 13 pages, 2018. View at: Publisher Site | Google Scholar
  22. X. Ma, R. Chen, X. Liu, J. Xie, K. Si, and L. Duan, “Effects of matrine on JAK-STAT signaling transduction pathways in bleomycin-induced pulmonary fibrosis,” African Journal of Traditional, Complementary, and Alternative Medicines, vol. 10, no. 3, pp. 442–448, 2013. View at: Publisher Site | Google Scholar

Copyright © 2020 Yan-jun Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder
Views312
Downloads298
Citations

Related articles

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.